Compare Constellation Energy Corporation (CEG) vs Gilead Sciences, Inc. (GILD) Price & Performance

Constellation Energy CorporationTrade

Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Constellation Energy Corporation vs Gilead Sciences, Inc. — how do they compare? Constellation Energy Corporation trades at $279.76 (market cap $95.82B), while Gilead Sciences, Inc. trades at $135 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.

	CEG	GILD
Market Cap	$95.82B	$164.99B
Sector	Energy	Health
52-Week High	$403.95	$155.80
52-Week Low	$236.50	$110.56
Enterprise Value	$119.82B	$188.06B
Dividend Yield	0.63%	2.47%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Constellation Energy Corporation

Constellation Energy (CEG) trades at $269.89, up 3.37% with a bullish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $2.55 versus $2.29 expected, and the company raised its 2026 guidance. Recent news highlights new power deals, including a Walmart PPA, and the acquisition of Calpine, positioning CEG to benefit from AI-driven electricity demand.

The outlook is positive with a consensus price target of $333.14, implying significant upside. Key opportunities include nuclear energy's role in the AI power boom and strong cash flow generation. Risks involve execution of growth initiatives and potential regulatory changes affecting the utilities sector.

Gilead Sciences, Inc.

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

CEG

Constellation Energy rated Strong Buy with price target raised to $449 on AI-driven nuclear contract growth.Seeking Alpha · 22 hours agoBullish Constellation Energy rated BUY for strong growth, hybrid fleet, and AI-driven electricity demand.Seeking Alpha · 4 days agoBullish View details →

GILD

Gilead upgrades 2026 sales outlook as HIV drug Biktarvy and Livdelzi show strong growthSeeking Alpha · 2 days agoBullish 2026 National ORBIE Awards honor top CIOs and CISOs across key industry categories in San Jose.Inspire Leadership Network · 4 days agoNeutral View details →

About Constellation Energy Corporation

Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.